Hologic, Inc. (HOLX) Director Sells $278,706.56 in Stock
Hologic, Inc. (NASDAQ:HOLX) Director Lawrence M. Levy sold 7,139 shares of the stock in a transaction that occurred on Thursday, September 7th. The stock was sold at an average price of $39.04, for a total transaction of $278,706.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Hologic, Inc. (NASDAQ:HOLX) traded up 1.03% during midday trading on Monday, reaching $39.20. 3,326,646 shares of the company traded hands. Hologic, Inc. has a 1-year low of $35.15 and a 1-year high of $46.80. The firm has a 50-day moving average of $39.73 and a 200-day moving average of $42.70. The stock has a market capitalization of $10.99 billion, a P/E ratio of 14.60 and a beta of 0.92.
Hologic (NASDAQ:HOLX) last released its earnings results on Wednesday, August 2nd. The medical equipment provider reported $0.50 EPS for the quarter, topping the Zacks’ consensus estimate of $0.49 by $0.01. Hologic had a return on equity of 23.18% and a net margin of 25.65%. The firm had revenue of $806.10 million during the quarter, compared to the consensus estimate of $799.70 million. During the same quarter in the previous year, the company posted $0.51 earnings per share. The company’s revenue was up 12.4% compared to the same quarter last year. On average, analysts predict that Hologic, Inc. will post $2.01 earnings per share for the current year.
COPYRIGHT VIOLATION NOTICE: “Hologic, Inc. (HOLX) Director Sells $278,706.56 in Stock” was published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of United States and international trademark & copyright laws. The correct version of this piece of content can be read at https://www.watchlistnews.com/hologic-inc-holx-director-sells-278706-56-in-stock/1555322.html.
Institutional investors have recently added to or reduced their stakes in the stock. Russell Investments Group Ltd. lifted its holdings in Hologic by 229.7% in the second quarter. Russell Investments Group Ltd. now owns 1,059,586 shares of the medical equipment provider’s stock valued at $48,100,000 after acquiring an additional 738,215 shares during the period. Rhumbline Advisers lifted its holdings in Hologic by 1.4% in the second quarter. Rhumbline Advisers now owns 548,465 shares of the medical equipment provider’s stock valued at $24,889,000 after acquiring an additional 7,727 shares during the period. Teachers Advisors LLC lifted its holdings in Hologic by 36.4% in the first quarter. Teachers Advisors LLC now owns 877,549 shares of the medical equipment provider’s stock valued at $37,340,000 after acquiring an additional 234,002 shares during the period. Earnest Partners LLC lifted its holdings in Hologic by 168,145.9% in the first quarter. Earnest Partners LLC now owns 205,260 shares of the medical equipment provider’s stock valued at $8,734,000 after acquiring an additional 205,138 shares during the period. Finally, ING Groep NV lifted its holdings in Hologic by 0.7% in the second quarter. ING Groep NV now owns 60,750 shares of the medical equipment provider’s stock valued at $2,757,000 after acquiring an additional 406 shares during the period. 96.39% of the stock is owned by hedge funds and other institutional investors.
Several equities analysts have recently weighed in on HOLX shares. Royal Bank Of Canada lowered their price objective on shares of Hologic from $50.00 to $45.00 and set a “sector perform” rating on the stock in a research note on Thursday, August 3rd. BidaskClub cut shares of Hologic from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, July 25th. Zacks Investment Research upgraded shares of Hologic from a “sell” rating to a “hold” rating in a research note on Friday, August 4th. Barclays PLC lowered their price objective on shares of Hologic from $53.00 to $51.00 and set an “overweight” rating on the stock in a research note on Thursday, August 3rd. Finally, Needham & Company LLC reiterated a “buy” rating on shares of Hologic in a research note on Tuesday, August 1st. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and nine have assigned a buy rating to the company. Hologic has an average rating of “Buy” and an average target price of $48.64.
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.
Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.